Hyperliquid Strategies Inc and Sonnet BioTherapeutics Holdings, Inc. Announce Closing of Business Combination
Trading on The Nasdaq Capital Market under the ticker symbol “PURR”
| Date | Form | Description | XBRL | Pages | |
|---|---|---|---|---|---|
| 05/15/17 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) |
|
   |
42 |
| 05/15/17 | 8-K | Current report filing |
|
13 | |
| 05/11/17 | D | Official notice of an offering of securities that is made without registration under the Securities Act in reliance on an exemption provided by Regulation D and Section 4(a)(5) under the Act. |
|
6 | |
| 05/05/17 | 8-K | Current report filing |
|
139 | |
| 04/19/17 | DEF 14A | Definitive proxy statements |
|
30 | |
| 04/13/17 | UPLOAD | SEC-generated letter |
|
1 | |
| 04/12/17 | CORRESP | A correspondence can be sent as a document with another submission type or can be sent as a separate submission. |
|
3 | |
| 04/12/17 | PRER14A | Preliminary revised proxy soliciting materials |
|
30 | |
| 04/10/17 | UPLOAD | SEC-generated letter |
|
2 | |
| 04/04/17 | 8-K | Current report filing |
|
4 |
